Using a filtration technique to isolate platelet free plasma for assaying pyrophosphate
- PMID: 23289181
- PMCID: PMC4733525
Using a filtration technique to isolate platelet free plasma for assaying pyrophosphate
Abstract
Background: Vascular calcification (VC) is a strong prognostic marker of mortality from cardiovascular disease. Extracellular inorganic pyrophosphate (PPi) is a critical inhibitor of vascular calcification and it has been reported that hemodialysis patients have reduced plasma PPi levels, suggesting that altered PPi metabolism could contribute to VC in hemodialysis patients. Platelets are rich in PPi and release of PPi from platelets during storage or processing of plasma can lead to falsely elevated plasma PPi levels. To prepare plasma samples that are suitable for measuring PPi levels, ultracentrifugation has been used to remove platelets. Consequently, plasma PPi measurements have been limited to research laboratories since the majority of clinical laboratories do not have access to an ultracentrifuge. The purpose of the present study was to test the validity of an improved method of preparing platelet free plasma that uses filtration with a 300,000 Dalton molecular weight cut-off filter to exclude platelets, while minimizing their release of PPi.
Methods: In 20 maintenance hemodialysis patients, PPi levels were measured in plasma samples prepared by the conventional technique of low-speed centrifugation to remove red and white blood cells versus a novel filtration technique.
Results: Plasma prepared by filtration had significantly lower platelet counts (0 vs. 3 - 7 10(3)/microL) and PPi levels (1.39 +/- 0.30 microM vs. 2.74 +/- 1.19 microM; mean +/- SD, p < 0.01).
Conclusions: The filtration method appears effective in excluding platelets without causing trauma to platelets and can be used by clinical laboratories to prepare platelet-depleted plasma for PPi measurement.
Conflict of interest statement
None
Figures
References
-
- Jono S, Shioi A, Ikari Y, Nishizawa Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab. 2006;24(2):176–81. - PubMed
-
- Merjanian R, Budoff M, Adler S, Berman N, Mehrotra R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 2003;64(1):263–71. - PubMed
-
- Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212(5065):901–3. - PubMed
-
- Russell RG, Fleisch H. Inorganic pyrophosphate and pyrophosphatases in calcification and calcium homeostasis. Clin Orthop Relat Res. 1970;69:101–17. - PubMed
-
- Fleisch H, Russell RG. A review of the physiological and pharmacological effects of pyrophosphate and diphosphonates on bones and teeth. J Dent Res. 1972;51(2):324–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources